UBS O'Connor’s Thrive Acquisition Corporation Class A ordinary shares THAC Stock Holding History

UBS O'Connor’s Portfolio THAC Stock Details THAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-236,311	Closed	-$2.44M	–	868
2022 Q4	$2.44M	Sell	236,311 -2,312	-1%	-$23.7K	0.05%	360
2022 Q3	$2.42M	Sell	238,623 -23,888	-9%	-$241K	0.03%	507
2022 Q2	$2.64M	Hold	262,511	–	–	0.03%	500
2022 Q1	$2.62M	Buy	262,511 +4,626	+2%	+$46K	0.03%	465
2021 Q4	$2.57M	Buy	+257,885	New	+$2.55M	0.02%	446

UBS O'Connor's THAC Position: Q1 2023 in Review

UBS O'Connor sold out of Thrive Acquisition Corporation Class A ordinary shares (THAC) in Q1 2023, closing a stake of 236,311 shares — an estimated $2.44M sold.

UBS O'Connor first reported a position in THAC in Q4 2021 and held it in 5 quarters. The position peaked at $2.64M in Q2 2022. 0 funds tracked by Wall St. Rank hold THAC as of Q1 2023.

UBS O'Connor reported no remaining Thrive Acquisition Corporation Class A ordinary shares position as of Q1 2023 after selling out during the quarter.
UBS O'Connor sold 236,311 Thrive Acquisition Corporation Class A ordinary shares shares in Q1 2023, an estimated $2.44M.
UBS O'Connor first reported a position in Thrive Acquisition Corporation Class A ordinary shares in Q4 2021 and held it in 5 quarters.
UBS O'Connor's Thrive Acquisition Corporation Class A ordinary shares position peaked at $2.64M in Q2 2022.
0 funds tracked by Wall St. Rank held Thrive Acquisition Corporation Class A ordinary shares as of Q1 2023.

Based on UBS O'Connor's 13F filing for Q1 2023, filed 15 May 2023.